TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06300372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-TAPA plane block
Description: As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied bilaterally (60 ml in total).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative pain management
Description: For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain management
Description: For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.
Study: NCT06382155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide Injection
Description: Experimental Drug Lyophilized powder for reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide Injection
Description: Experimental Drug Lyophilized powder for reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide Injection
Description: Experimental Drug Lyophilized powder for reconstitution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Growth Hormone
Description: Commercial product containing somatotropin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized powder for reconstitution
Study: NCT06003127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation and measurement of related evoked potentials in the EEG.
Study: NCT06016972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: QLS-111 ophthalmic solution, (0.015%)
Description: QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: QLS-111 ophthalmic solution, (0.03%)
Description: QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: QLS-111 ophthalmic solution, (0.075%)
Description: QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QLS-111 ophthalmic vehicle solution
Description: Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Study: NCT05790863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergometer cycling
Description: Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ergometer cycling
Description: Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
Study: NCT06635980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo breast biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo breast biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Undergo breast surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Undergo breast surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive SOC chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive SOC chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Digital Mammography
Description: Undergo CEDM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Digital Mammography
Description: Undergo CEDM

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Collection
Description: Undergo tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Collection
Description: Undergo tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound
Study: NCT06636383

Intervention type: OTHER
Intervention: No Intervention
Description: No investigational/study product will be administered in this DMP.

Intervention type: OTHER
Intervention: No Intervention
Description: No investigational/study product will be administered in this DMP.
Study: NCT06183931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2220
Description: Participants will receive ALXN2220 via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo via IV infusion.
Study: NCT05953662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced-port laparoscopic surgery
Description: compare different operational styles of colon and upper rectal cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic surgery
Description: conventional laparoscopic surgery
Study: NCT04985760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant
Description: Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant
Description: Volume matched control for Trimer 4571 vaccine 100mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Description: Investigational vaccine composed of Trimer 4571 500mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
Study: NCT05182801

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: Blank

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Banana flower extract sachet
Description: Happy Angel Banana Flower Extract sachet
Study: NCT05681364

Intervention type: OTHER
Intervention: metabonomics
Description: profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation

Intervention type: OTHER
Intervention: metabonomics
Description: profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation
Study: NCT05017805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines
Description: One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines
Description: One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively.
Study: NCT06260917

Intervention type: DIAGNOSTIC_TEST
Intervention: position of urination
Description: effect of position on uroflowmetry parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: position of urination
Description: effect of position on uroflowmetry parameters
Study: NCT04985760

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Description: Volume matched control for Trimer 4571 vaccine 500mcg
Study: NCT05658562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2111
Description: i.v. infusion
Study: NCT06629818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)
Description: qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 400mg po qd for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months
Study: NCT05328362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CanCope
Description: Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
Study: NCT05562297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Patients firstly receive sintilimab 200 mg (iv, 30 minutes) on day 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 125 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT05828680

Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study: NCT06407791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LymphaVibe
Description: The LymphaVibe is a newly-developed device that uses a vibratory sequence to gently move stagnant lymphatic fluid from the arm to the nearest group of functioning lymph nodes
Study: NCT05314374

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ileocolonic-release conjugated bile acid
Description: 1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks exactly like the study drug, but it contains no active ingredient. 1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days.
Study: NCT06298318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vodka
Description: BMI: if 18.5 ≤ BMI \< 24.0, individuals received 1.0 g/kg body weight of vodka; if 24.0 ≤ BMI ≤ 28.0, individuals received 0.8 g/kg body weight of vodka.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
Study: NCT05996107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 400 mg daily with a possibly dose reduction to 200 mg daily if required

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative Radiation Therapy
Description: 50 Gy in 25 fractions or 42.56 Gy in 16 fraction +/- 10 Gy boost including comprehensive nodal
Study: NCT04415372

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Testing
Description: A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Testing
Description: A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.
Study: NCT05341817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
Study: NCT04855175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Bone Allograft (ClearFit)
Description: Patients in this arm will receive ClearFit (synthetic bone allograft)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autograft
Description: Patients in this arm will use patient's own bone
Study: NCT06292923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foralumab
Description: Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foralumab
Description: Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Foralumab placebo nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).
Study: NCT05784246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab SC
Description: Administered SC
Study: NCT06008730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiology, Treatment Planning
Description: Undergo radiation treatment planning
Study: NCT04658433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg of omega3-FA
Description: The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
Study: NCT06053632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-load and high-velocity - lying prone - eccentric hamstring exercise
Description: Low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks.
Study: NCT06487507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low fat diet
Description: Prior to surgery, participants complete diet records for 7 days. After, they will receive one shipment containing prepared meals (refrigerated, frozen and fresh) low fat Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track their food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet
Description: Prior to surgery, participants complete diet records for 7 days. After, they will receive one shipment containing prepared meals (refrigerated, frozen and fresh) lower carbohydrate Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track their food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
Study: NCT05704634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by Injection under the skin every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by Injection under the skin every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kevzara (Sarilumab)
Description: Given by IV (vein) over about 30 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kevzara (Sarilumab)
Description: Given by IV (vein) over about 30 minutes every 3 weeks.
Study: NCT06143514

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06501989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biweekly 5-FLUOROURACIL (5-FU)
Description: 5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biweekly Modified FOLFOX6
Description: Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biweekly FOLFIRI
Description: Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.